UniProt P37173 · PDB · AlphaFold · Substrate: MBP · Clone: 190-end
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 90.8% | 9.2% | 78.23 | 0.534 |
| 2 | Vemurafenib | 86.4% | 13.6% | 96.49 | 0.598 |
| 3 | Dabrafenib | 72.6% | 27.4% | 94.74 | 0.633 |
| 4 | Pacritinib | 72.2% | 27.8% | 88.64 | 0.452 |
| 5 | Fedratinib | 41.1% | 58.9% | 96.21 | 0.576 |
| 6 | Lenvatinib | 35.5% | 64.5% | 97.74 | 0.726 |
| 7 | Erdafitinib | 32.6% | 67.4% | 95.71 | 0.737 |
| 8 | Canertinib | 30.1% | 69.9% | 96.49 | 0.671 |
| 9 | Pazopanib | 23.9% | 76.1% | 97.49 | 0.672 |
| 10 | Lorlatinib | 20.5% | 79.5% | 97.24 | 0.694 |
| 11 | Binimetinib | 19.7% | 80.3% | 100.00 | 0.689 |
| 12 | Selpercatinib | 17.2% | 82.8% | 96.72 | 0.635 |
| 13 | Gilteritinib | 17.1% | 82.9% | 88.97 | 0.506 |
| 14 | Pirtobrutinib | 17.1% | 82.9% | 99.49 | 0.656 |
| 15 | Dacomitinib | 16.4% | 83.6% | 97.99 | 0.664 |
| 16 | Tofacitinib | 15.3% | 84.7% | 99.25 | 0.684 |
| 17 | Pexidartinib | 14.1% | 85.9% | 99.49 | 0.631 |
| 18 | Tivozanib | 13.5% | 86.5% | 92.42 | 0.673 |
| 19 | Regorafenib | 13.5% | 86.5% | 95.99 | 0.719 |
| 20 | Fostamatinib | 13.4% | 86.6% | 96.74 | 0.613 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.57
- Epithelial log2(TPM+1): 3.17
- Fold change: 2.39
- Status: Upregulated
Selectivity landscape vs inhibition on TGFBR2
Each point is one of the 92 approved drugs; color = inhibition % on TGFBR2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…